Zotiraciclib

also known as TG02 · EX45 · SB-1317 · Sb-1317 free base · TG02 Citrate · ZOTIRACICLIB CITRATE · ZTR

Small molecule targets CDK1, CDK2, CDK7, CDK9, FLT3, JAK2 via inhibition

Developed for: acute myeloid leukemia · anaplastic astrocytoma · astrocytoma (excluding glioblastoma) · brain neoplasm · cancer · chronic lymphocytic leukemia/small lymphocytic lymphoma · glioblastoma · gliosarcoma
+4 more
· hepatocellular carcinoma · malignant glioma · plasma cell myeloma · rectal cancer
Investigated by: Tragara Pharmaceuticals, Inc. · Lee's Pharmaceutical Limited · National Cancer Institute (NCI) · China Oncology Focus Limited · European Organisation for Research and Treatment of Cancer - EORTC · Targovax ASA

Trials 8 · a red edge is where a trial was stopped

today NCT05588141 · Ph 1/2 NCT03904628 · Ph 1 NCT03738111 · Ph 1 NCT03224104 · Ph 1 NCT02942264 · Ph 1/2 NCT02933944 · Ph 1 NCT01699152 · Ph 1 NCT01204164 · Ph 1

2011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT03904628	Mar 2019 → Aug 2020	malignant glioma	Lee's Pharmaceutical Limited	Unknown	No outcome recorded
Phase 1	NCT03738111	Dec 2018 → Aug 2021	hepatocellular carcinoma	Lee's Pharmaceutical Limited	Withdrawn	No outcome recorded
Phase 1	NCT03224104	Jun 2018 → May 2022	anaplastic astrocytoma, glioblastoma	European Organisation for Research and Treatment of Cancer - EORTC	Completed	No outcome recorded
Phase 1	NCT02933944	Sep 2016 → Feb 2019	rectal cancer	Targovax ASA	Terminated	No outcome recorded
Phase 1	NCT01699152	Sep 2012 → Jul 2015	chronic lymphocytic leukemia/small lymphocytic lymphoma	Tragara Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT01204164	Aug 2010 → Mar 2016	acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome, plasma cell myeloma	Tragara Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT05588141	May 2023 → Aug 2028 expected	brain neoplasm, cancer	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT02942264	Dec 2016 → Aug 2020	astrocytoma (excluding glioblastoma), gliosarcoma	National Cancer Institute (NCI)	Terminated	No outcome recorded

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

Field	Value	Cited text
Known as	Zotiraciclib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02942264 ↗ 1 NCT05588141 ↗
Known as	EX45	ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗
Known as	SB-1317	ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗
Known as	Sb-1317 free base	ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗
Known as	TG02	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01699152 ↗ 5 NCT03224104 ↗ NCT03738111 ↗ NCT03904628 ↗ NCT02933944 ↗ NCT01204164 ↗
Known as	TG02 Citrate	“Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma” NCT03738111 ↗
Known as	ZOTIRACICLIB CITRATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗
Known as	ZTR	“Here, by conducting a high-throughput drug screen, we pinpointed a specific vulnerability of IDH-mutant gliomas to zotiraciclib (ZTR).” PMID 40241769 ↗ Mar 2025
Action	Inhibit	“Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and...” NCT02942264 ↗ 5 “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1944698 ↗ “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL1944698 ↗ “Cyclin-dependent kinase 1 inhibitor” CHEMBL1944698 ↗ “Cyclin-dependent kinase 2 inhibitor” CHEMBL1944698 ↗ “Cyclin-dependent kinase 7 inhibitor” CHEMBL1944698 ↗
Modality	Small molecule	— CHEMBL1944698 ↗
Route	Oral	“TG02 citrate capsules given orally.” NCT01204164 ↗
Target	CDK1	“Cyclin-dependent kinase 1 inhibitor” CHEMBL1944698 ↗
Target	CDK2	“Cyclin-dependent kinase 2 inhibitor” CHEMBL1944698 ↗
Target	CDK7	“Cyclin-dependent kinase 7 inhibitor” CHEMBL1944698 ↗
Target	CDK9	“Zotiraciclib (TG02) down-regulates cyclin-dependent kinase 9 (CDK9) activity” NCT02942264 ↗
Target	FLT3	“Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1944698 ↗
Target	JAK2	“Tyrosine-protein kinase JAK2 inhibitor” CHEMBL1944698 ↗